Our group is interested in cognitive neuroscience of psychiatric illness, with the broad objective of better understanding neural systems involved in cognitive and affective deficits via non-invasive neuroimaging.
Welcome to the Anticevic Lab:
Broadly, our group is interested in cognitive neuroscience of psychiatric illness. We seek to better understand, at the neural system level, the mechanisms behind cognitive and affective deficits in neuropsychiatric illness. Specifically, the research in our group focuses on understanding these processes in schizophrenia, bipolar illness and addiction. We use a combination of tools to better understand the underlying systems involved in processing affective stimuli and their interaction with circuits involved in goal-directed cognitive operations such as working memory.
Methodologically, our lab harnesses the combination of task-based, resting-state, pharmacological functional neuroimaging, as well as computational modeling approaches. Combining these approaches allows us to mechanistically understand neural circuit dysfunction in psychiatric disorders. Our experimental approaches depend on the combination of these tools to better understand the mechanistic links between dysfunction at the microcircuit level and complex cognitive and affective disturbances. The overarching objective of the lab is to better characterize the underlying neural circuit dysfunction in complex mental illness such as schizophrenia, with the aim of developing better neural markers and informing rationally-guided pharmacological treatments. The lab is also a close affiliate of the Center for the Translational Neuroscience of Alcoholism (CTNA) and the Division of Neurocognition, Neurocomputation, and Neurogenetics (N3).
NIMH highlights Anticevic Lab research in a sampling of summer science
Anticevic Lab receives the 2012 NIH Director’s Early Independence Award (DP5)
Anticevic Lab is awarded a 5-year grant to better characterize the neural mechanisms behind cognitive impairment in schizophrenia via the combination of pharmacological neuroimaging, computational modeling and non-invasive neuroimaging of clinical populations. The pharmacological work is done collaboratively with Dr. John H. Krystal and Dr. Peter T. Morgan. Computational modeling is being developed collaboratively with Dr. Xiao-Jing Wang and John D. Murray.
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.